Treatment planning in cutaneous T-cell lymphoma.
Effective long-term management of cutaneous T-cell lymphoma (CTCL) requires administration of skin-directed therapies such as topically applied nitrogen mustard or photochemotherapy to achieve a complete response in clinically early disease (patch and thin-plaque-phase mycosis fungoides, MF) and often the concomitant administration of well-tolerated drugs with systemic effects such as interferon alfa, bexarotene, methotrexate or extracorporeal photopheresis in more advanced, but not highly aggressive/nontransformed disease (thick plaque or tumor phase MF or erythrodermic CTCL). The author's approach is provided as a guide for dermatologists in private practice.
Vonderheid
Eric C
EC
Johns Hopkins Medical Institutes, Baltimore, Maryland 21205, USA. evonder1@jhmi.edu
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008722:Methods; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000628:therapy; D009367:Neoplasm Staging; D010778:Photochemotherapy / Q000379:methods*; D011379:Prognosis; D018570:Risk Assessment; D017678:Sex Distribution; D012878:Skin Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D016019:Survival Analysis; D016896:Treatment Outcome